Protease inhibitors and anticonvulsants.

J. Brooks, J. Daily, L. Schwamm

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Due to adverse interactions, manufacturers of four licensed protease inhibitors are recommending that their products not be used with the three most frequently prescribed anticonvulsants: carbamazepine, phenobarbitol, and phenytoin. These adverse interactions and their causes are discussed, suggesting that concomitant administration of protease inhibitors may induce early viral resistance and possibly accelerate HIV progression. Further, ritonavir and nelfinavir use may raise serum levels of these anticonvulsants into toxic ranges. Although not approved for single-agent use in the United States, two anticonvulsants that are theoretically less prone to interact adversely with protease inhibitors are gabapentin and lamotrigine. Protocols to manage patients on protease inhibitors and anticonvulsants are suggested.

Original languageEnglish (US)
Pages (from-to)87, 90
JournalAIDS clinical care
Issue number11
StatePublished - Nov 1997
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Protease inhibitors and anticonvulsants.'. Together they form a unique fingerprint.

Cite this